Mavenclad and Venclexta combination achieved a 96% ORR in newly diagnosed AML and high-risk MDS patients, with high CR rates in MRD-negative individuals. The study reported a 2-year OS rate of 100% ...
Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...
“The success of the SELECT-MDS-1 trial was as an efficiently accrued international phase 3 trial that was biomarker driven, the first of its kind in MDS. Although the doublet combination tested in ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
The BEXERA trial (FP2CLI012) is a randomized, double-blind, placebo-controlled Phase IIb trial in treatment-naïve HR-MDS. Planned to start in the second half of 2026, the trial will evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results